Rising multiple-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy smokers Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CSCR2, in healthy volunteers Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
Effects of oral SCH 527123, a CXCR2 antagonist, on acquired immunity in healthy adults Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004
Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
The efficacy and safety of long-acting muscarinic antagonist treatment for COPD Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma Year: 2019
Superior in vivo efficacy of macitentan: Comparison to other endothelin receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007
The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist, Viozan™ (AR-C68397AA) improves quality of life and perception of efficacy Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019
Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists Source: Eur Respir Monogr 2020; 88: 238-250 Year: 2020
Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012